GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Other Financing

Alliance Pharma (LSE:APH) Other Financing : £-7.5 Mil (TTM As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Other Financing?

Alliance Pharma's Other Financing for the six months ended in Jun. 2023 was £-4.4 Mil.

Alliance Pharma's Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 was £-7.5 Mil.


Alliance Pharma Other Financing Historical Data

The historical data trend for Alliance Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Other Financing Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.56 -3.91 -3.23 -2.97 -4.80

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.48 -1.48 -1.71 -3.10 -4.40

Alliance Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-7.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma Other Financing Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q3 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

The Amphenol Corp (APH) Company: A Short SWOT Analysis

By GuruFocus Research 10-30-2023

Q4 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amphenol Announces Third Quarter 2023 Dividend

By Business Wire 08-04-2023

Q4 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024